OpenAI 收购 Orchestra Bio，其 AI 智能体负责追踪药物项目进展
OpenAI 收购 Orchestra Bio，该平台的 AI 智能体负责追踪药物研发项目，团队与技术将并入生命科学研究工具 Rosalind。Orchestra 的智能体监控研究与时间线，当生产批次失败时可映射受影响的试验并汇总应对选项供项目负责人选择。
Rohan Paul· @rohanpaul_ai · X·2026-10-21 02:58· 47 分钟前AI 评分54
AI 导读
OpenAI 收购 Orchestra Bio，一个帮助生物制药团队协调药物开发流程的平台，其团队和技术将与生命科学研究工具 Rosalind 整合。Orchestra 的智能体监控研究与时间线，当生产批次失败时可映射哪些试验受影响并汇总应对选项；此前 Anthropic 已于 4 月以约 $400M 股票收购 Coefficient Bio。新药从靶点发现到美国审批平均仍需 10 到 15 年。
正文 · 原文
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
Until now, Rosalind covered the science: GPT-Rosalind reasons through biology and chemistry, while Rosalind Workbench links models to lab tools and data.
Orchestra targets a different bottleneck, the coordination work that spreads a drug program across departments, contractors and disconnected software.
Its agents monitor studies and timelines, so when a manufacturing batch fails, they map which trials slip and compare responses for program leaders to choose.
Anthropic paid roughly $400M in stock for Coefficient Bio in April, so both labs are now buying specialist biology teams.
Development still averages 10 to 15 years from target to US approval, a clock largely set by trial biology and regulators.
来源：Rohan Paul · x.com
来源：RadarAI · aihot.news